Modified power prior with multiple historical trials for binary endpoints

Including historical data may increase the power of the analysis of a current clinical trial and reduce the sample size of the study. Recently, several Bayesian methods for incorporating historical data have been proposed. One of the methods consists of specifying a so-called power prior whereby the historical likelihood is downweighted with a weight parameter. When the weight parameter is also estimated from the data, the modified power prior (MPP) is needed. This method has been used primarily when a single historical trial is available. We have adapted the MPP for incorporating multiple historical control arms into a current clinical trial, each with a separate weight parameter. Three priors for the weights are considered: (1) independent, (2) dependent, and (3) robustified dependent. The latter is developed to account for the possibility of a conflict between the historical data and the current data. We analyze two real-life data sets and perform simulation studies to compare the performance of competing Bayesian methods that allow to incorporate historical control patients in the analysis of a current trial. The dependent power prior borrows more information from comparable historical studies and thereby can improve the statistical power. Robustifying the dependent power prior seems to protect against prior-data conflict.

[1]  J. Beyene,et al.  Hematopoietic colony-stimulating factor priming does not influence survival in acute myeloid leukemia: a meta-analysis of randomized trials , 2009, Leukemia.

[2]  Xiao-Li Meng,et al.  Simulating Normalizing Constants: From Importance Sampling to Bridge Sampling to Path Sampling , 1998 .

[3]  S J Pocock,et al.  The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.

[4]  Keying Ye,et al.  Evaluating water quality using power priors to incorporate historical information , 2006 .

[5]  L Ryan,et al.  Using historical controls in the analysis of developmental toxicity data. , 1993, Biometrics.

[6]  Joseph G. Ibrahim,et al.  Power prior distributions for generalized linear models , 2000 .

[7]  J. Ibrahim,et al.  Power prior distributions for regression models , 2000 .

[8]  J. Mate,et al.  Systematic review: infliximab therapy in ulcerative colitis , 2006, Alimentary pharmacology & therapeutics.

[9]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[10]  Ralf Bender,et al.  Methods to estimate the between‐study variance and its uncertainty in meta‐analysis† , 2015, Research synthesis methods.

[11]  J M Kendall,et al.  Designing a research project: randomised controlled trials and their principles , 2003, Emergency medicine journal : EMJ.

[12]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[13]  Bradley P Carlin,et al.  Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. , 2012, Bayesian analysis.

[14]  Yvette van Norden,et al.  Including historical data in the analysis of clinical trials: Is it worth the effort? , 2017, Statistical methods in medical research.

[15]  Augustin Ferrant,et al.  Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. , 2003, The New England journal of medicine.

[16]  Michael Branson,et al.  A note on the power prior , 2009, Statistics in medicine.

[17]  D. Spiegelhalter,et al.  Summarizing historical information on controls in clinical trials , 2010, Clinical trials.

[18]  E. George,et al.  Journal of the American Statistical Association is currently published by American Statistical Association. , 2007 .

[19]  Y. Min,et al.  A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. , 2011, Blood.

[20]  Bob Löwenberg,et al.  Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON‐SAKK co‐operative group studies , 2005, British journal of haematology.

[21]  Martyn Plummer,et al.  JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling , 2003 .

[22]  Bradley P Carlin,et al.  Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials , 2011, Biometrics.

[23]  A. Pettitt,et al.  Marginal likelihood estimation via power posteriors , 2008 .

[24]  Anthony O'Hagan,et al.  Robust meta‐analytic‐predictive priors in clinical trials with historical control information , 2014, Biometrics.

[25]  S. Targan,et al.  Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial , 2006, Gut.

[26]  Michael Evans,et al.  Checking for prior-data conflict , 2006 .